DDX17 and central nervous system cancer: In a variety of cancers, such as colon, breast, prostate, non-small cell lung, glioma, and hepatocellular carcinoma, DDX17 promotes cancer cell proliferation and inhibits apoptosis through the activation or inhibition of specific signaling pathways, thereby promoting tumorigenesis and progression (Figure 2) (21, 22, 29, 30).